Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

A Recurrent Activating Missense Mutation in Waldenström Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances Proliferation.

Roos-Weil D, Decaudin C, Armand M, Della-Valle V, Diop MK, Ghamlouch H, Ropars V, Hérate C, Lara D, Durot E, Haddad R, Mylonas E, Damm F, Pflumio F, Stoilova B, Metzner M, Elemento O, Dessen P, Camara-Clayette V, Cosset FL, Verhoeyen E, Leblond V, Ribrag V, Cornillet-Lefebvre P, Rameau P, Azar N, Charlotte F, Morel P, Charbonnier JB, Vyas P, Mercher T, Aoufouchi S, Droin N, Guillouf C, Nguyen-Khac F, Bernard OA.

Cancer Discov. 2019 Jun;9(6):796-811. doi: 10.1158/2159-8290.CD-18-0873. Epub 2019 Apr 24.

PMID:
31018969
2.

[Pediatric de novo acute megakaryoblastic leukemia: an affair of complexes].

Lopez CK, Mercher T.

Med Sci (Paris). 2018 Nov;34(11):954-962. doi: 10.1051/medsci/2018237. Epub 2018 Dec 10. Review. French.

PMID:
30526836
3.

Chromosomal Translocation Formation Is Sufficient to Produce Fusion Circular RNAs Specific to Patient Tumor Cells.

Babin L, Piganeau M, Renouf B, Lamribet K, Thirant C, Deriano L, Mercher T, Giovannangeli C, Brunet EC.

iScience. 2018 Jul 27;5:19-29. doi: 10.1016/j.isci.2018.06.007. Epub 2018 Jun 19.

4.

Partial trisomy 21 contributes to T-cell malignancies induced by JAK3-activating mutations in murine models.

Rivera-Munoz P, Laurent AP, Siret A, Lopez CK, Ignacimouttou C, Cornejo MG, Bawa O, Rameau P, Bernard OA, Dessen P, Gilliland GD, Mercher T, Malinge S.

Blood Adv. 2018 Jul 10;2(13):1616-1627. doi: 10.1182/bloodadvances.2018016089.

5.

B-cell tumor development in Tet2-deficient mice.

Mouly E, Ghamlouch H, Della-Valle V, Scourzic L, Quivoron C, Roos-Weil D, Pawlikowska P, Saada V, Diop MK, Lopez CK, Fontenay M, Dessen P, Touw IP, Mercher T, Aoufouchi S, Bernard OA.

Blood Adv. 2018 Mar 27;2(6):703-714. doi: 10.1182/bloodadvances.2017014118.

6.

AIF loss deregulates hematopoiesis and reveals different adaptive metabolic responses in bone marrow cells and thymocytes.

Cabon L, Bertaux A, Brunelle-Navas MN, Nemazanyy I, Scourzic L, Delavallée L, Vela L, Baritaud M, Bouchet S, Lopez C, Quang Van V, Garbin K, Chateau D, Gilard F, Sarfati M, Mercher T, Bernard OA, Susin SA.

Cell Death Differ. 2018 May;25(5):983-1001. doi: 10.1038/s41418-017-0035-x. Epub 2018 Jan 11.

7.

Acute megakaryoblastic leukemia (excluding Down syndrome) remains an acute myeloid subgroup with inferior outcome in the French ELAM02 trial.

Teyssier AC, Lapillonne H, Pasquet M, Ballerini P, Baruchel A, Ducassou S, Fenneteau O, Petit A, Cuccuini W, Ragu C, Preudhomme C, Mercher T, Sirvent N, Leverger G.

Pediatr Hematol Oncol. 2017 Nov;34(8):425-427. doi: 10.1080/08880018.2017.1414905. Epub 2018 Jan 5.

PMID:
29303660
8.

Molecular pathways driven by ETO2-GLIS2 in aggressive pediatric leukemia.

Thirant C, Lopez C, Malinge S, Mercher T.

Mol Cell Oncol. 2017 Sep 26;4(6):e1345351. doi: 10.1080/23723556.2017.1345351. eCollection 2017.

9.

Pediatric Acute Megakaryoblastic Leukemia: Multitasking Fusion Proteins and Oncogenic Cooperations.

Lopez CK, Malinge S, Gaudry M, Bernard OA, Mercher T.

Trends Cancer. 2017 Sep;3(9):631-642. doi: 10.1016/j.trecan.2017.07.003. Epub 2017 Aug 18. Review.

PMID:
28867167
10.

ETO2-GLIS2 Hijacks Transcriptional Complexes to Drive Cellular Identity and Self-Renewal in Pediatric Acute Megakaryoblastic Leukemia.

Thirant C, Ignacimouttou C, Lopez CK, Diop M, Le Mouël L, Thiollier C, Siret A, Dessen P, Aid Z, Rivière J, Rameau P, Lefebvre C, Khaled M, Leverger G, Ballerini P, Petit A, Raslova H, Carmichael CL, Kile BT, Soler E, Crispino JD, Wichmann C, Pflumio F, Schwaller J, Vainchenker W, Lobry C, Droin N, Bernard OA, Malinge S, Mercher T.

Cancer Cell. 2017 Mar 13;31(3):452-465. doi: 10.1016/j.ccell.2017.02.006.

11.

DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice.

Scourzic L, Couronné L, Pedersen MT, Della Valle V, Diop M, Mylonas E, Calvo J, Mouly E, Lopez CK, Martin N, Fontenay M, Bender A, Guibert S, Dubreuil P, Dessen P, Droin N, Pflumio F, Weber M, Gaulard P, Helin K, Mercher T, Bernard OA.

Leukemia. 2016 Jun;30(6):1388-98. doi: 10.1038/leu.2016.29. Epub 2016 Feb 15.

12.

Acquired initiating mutations in early hematopoietic cells of CLL patients.

Damm F, Mylonas E, Cosson A, Yoshida K, Della Valle V, Mouly E, Diop M, Scourzic L, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Kikushige Y, Davi F, Lambert J, Gautheret D, Merle-Béral H, Sutton L, Dessen P, Solary E, Akashi K, Vainchenker W, Mercher T, Droin N, Ogawa S, Nguyen-Khac F, Bernard OA.

Cancer Discov. 2014 Sep;4(9):1088-101. doi: 10.1158/2159-8290.CD-14-0104. Epub 2014 Jun 11.

13.

TET2 deficiency inhibits mesoderm and hematopoietic differentiation in human embryonic stem cells.

Langlois T, da Costa Reis Monte-Mor B, Lenglet G, Droin N, Marty C, Le Couédic JP, Almire C, Auger N, Mercher T, Delhommeau F, Christensen J, Helin K, Debili N, Fuks F, Bernard OA, Solary E, Vainchenker W, Plo I.

Stem Cells. 2014 Aug;32(8):2084-97. doi: 10.1002/stem.1718.

14.

STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model.

Couronné L, Scourzic L, Pilati C, Della Valle V, Duffourd Y, Solary E, Vainchenker W, Merlio JP, Beylot-Barry M, Damm F, Stern MH, Gaulard P, Lamant L, Delabesse E, Merle-Beral H, Nguyen-Khac F, Fontenay M, Tilly H, Bastard C, Zucman-Rossi J, Bernard OA, Mercher T.

Haematologica. 2013 Nov;98(11):1748-52. doi: 10.3324/haematol.2013.085068. Epub 2013 Jul 19.

15.

Developmental changes in human megakaryopoiesis.

Bluteau O, Langlois T, Rivera-Munoz P, Favale F, Rameau P, Meurice G, Dessen P, Solary E, Raslova H, Mercher T, Debili N, Vainchenker W.

J Thromb Haemost. 2013 Sep;11(9):1730-41. doi: 10.1111/jth.12326.

16.

JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma.

Bouchekioua A, Scourzic L, de Wever O, Zhang Y, Cervera P, Aline-Fardin A, Mercher T, Gaulard P, Nyga R, Jeziorowska D, Douay L, Vainchenker W, Louache F, Gespach C, Solary E, Coppo P.

Leukemia. 2014 Feb;28(2):338-48. doi: 10.1038/leu.2013.157. Epub 2013 May 21.

PMID:
23689514
17.

TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS.

Deplus R, Delatte B, Schwinn MK, Defrance M, Méndez J, Murphy N, Dawson MA, Volkmar M, Putmans P, Calonne E, Shih AH, Levine RL, Bernard O, Mercher T, Solary E, Urh M, Daniels DL, Fuks F.

EMBO J. 2013 Mar 6;32(5):645-55. doi: 10.1038/emboj.2012.357. Epub 2013 Jan 25.

18.

Ikaros inhibits megakaryopoiesis through functional interaction with GATA-1 and NOTCH signaling.

Malinge S, Thiollier C, Chlon TM, Doré LC, Diebold L, Bluteau O, Mabialah V, Vainchenker W, Dessen P, Winandy S, Mercher T, Crispino JD.

Blood. 2013 Mar 28;121(13):2440-51. doi: 10.1182/blood-2012-08-450627. Epub 2013 Jan 18.

19.

[Novel ETO2-GLIS2 fusion and therapeutic strategy in acute megakaryoblastic leukemia].

Thiollier C, Pflumio F, Ballerini P, Crispino JD, Bernard O, Mercher T.

Med Sci (Paris). 2012 Nov;28(11):1013-6. doi: 10.1051/medsci/20122811025. Epub 2012 Nov 12. French. No abstract available.

20.

STAT5 is crucial to maintain leukemic stem cells in acute myelogenous leukemias induced by MOZ-TIF2.

Tam WF, Hähnel PS, Schüler A, Lee BH, Okabe R, Zhu N, Pante SV, Raffel G, Mercher T, Wernig G, Bockamp E, Sasca D, Kreft A, Robinson GW, Hennighausen L, Gilliland DG, Kindler T.

Cancer Res. 2013 Jan 1;73(1):373-84. doi: 10.1158/0008-5472.CAN-12-0255. Epub 2012 Nov 13.

21.

In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells.

Soucie E, Hanssens K, Mercher T, Georgin-Lavialle S, Damaj G, Livideanu C, Chandesris MO, Acin Y, Létard S, de Sepulveda P, Hermine O, Bernard OA, Dubreuil P.

Blood. 2012 Dec 6;120(24):4846-9. doi: 10.1182/blood-2011-12-397588. Epub 2012 Oct 16.

PMID:
23074272
22.

Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models.

Thiollier C, Lopez CK, Gerby B, Ignacimouttou C, Poglio S, Duffourd Y, Guégan J, Rivera-Munoz P, Bluteau O, Mabialah V, Diop M, Wen Q, Petit A, Bauchet AL, Reinhardt D, Bornhauser B, Gautheret D, Lecluse Y, Landman-Parker J, Radford I, Vainchenker W, Dastugue N, de Botton S, Dessen P, Bourquin JP, Crispino JD, Ballerini P, Bernard OA, Pflumio F, Mercher T.

J Exp Med. 2012 Oct 22;209(11):2017-31. doi: 10.1084/jem.20121343. Epub 2012 Oct 8.

23.

Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL.

Wen Q, Goldenson B, Silver SJ, Schenone M, Dancik V, Huang Z, Wang LZ, Lewis TA, An WF, Li X, Bray MA, Thiollier C, Diebold L, Gilles L, Vokes MS, Moore CB, Bliss-Moreau M, Verplank L, Tolliday NJ, Mishra R, Vemula S, Shi J, Wei L, Kapur R, Lopez CK, Gerby B, Ballerini P, Pflumio F, Gilliland DG, Goldberg L, Birger Y, Izraeli S, Gamis AS, Smith FO, Woods WG, Taub J, Scherer CA, Bradner JE, Goh BC, Mercher T, Carpenter AE, Gould RJ, Clemons PA, Carr SA, Root DE, Schreiber SL, Stern AM, Crispino JD.

Cell. 2012 Aug 3;150(3):575-89. doi: 10.1016/j.cell.2012.06.032.

24.

RUNX1-induced silencing of non-muscle myosin heavy chain IIB contributes to megakaryocyte polyploidization.

Lordier L, Bluteau D, Jalil A, Legrand C, Pan J, Rameau P, Jouni D, Bluteau O, Mercher T, Leon C, Gachet C, Debili N, Vainchenker W, Raslova H, Chang Y.

Nat Commun. 2012 Mar 6;3:717. doi: 10.1038/ncomms1704.

PMID:
22395608
25.

A functional role for the histone demethylase UTX in normal and malignant hematopoietic cells.

Liu J, Mercher T, Scholl C, Brumme K, Gilliland DG, Zhu N.

Exp Hematol. 2012 Jun;40(6):487-98.e3. doi: 10.1016/j.exphem.2012.01.017. Epub 2012 Feb 1.

PMID:
22306297
26.

TET2, a tumor suppressor in hematological disorders.

Mercher T, Quivoron C, Couronné L, Bastard C, Vainchenker W, Bernard OA.

Biochim Biophys Acta. 2012 Apr;1825(2):173-7. doi: 10.1016/j.bbcan.2011.12.002. Epub 2012 Jan 3. Review.

PMID:
22240200
27.

[In cauda venenum or the importance of TET(2)].

Mercher T, Quivoron C, Couronné L, Vainchenker W, Bastard C, Bernard OA.

Med Sci (Paris). 2011 Dec;27(12):1064-6. doi: 10.1051/medsci/20112712009. Epub 2011 Dec 23. French. No abstract available.

28.

TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis.

Quivoron C, Couronné L, Della Valle V, Lopez CK, Plo I, Wagner-Ballon O, Do Cruzeiro M, Delhommeau F, Arnulf B, Stern MH, Godley L, Opolon P, Tilly H, Solary E, Duffourd Y, Dessen P, Merle-Beral H, Nguyen-Khac F, Fontenay M, Vainchenker W, Bastard C, Mercher T, Bernard OA.

Cancer Cell. 2011 Jul 12;20(1):25-38. doi: 10.1016/j.ccr.2011.06.003. Epub 2011 Jun 30.

29.

Crosstalk between NOTCH and AKT signaling during murine megakaryocyte lineage specification.

Cornejo MG, Mabialah V, Sykes SM, Khandan T, Lo Celso C, Lopez CK, Rivera-Muñoz P, Rameau P, Tothova Z, Aster JC, DePinho RA, Scadden DT, Gilliland DG, Mercher T.

Blood. 2011 Aug 4;118(5):1264-73. doi: 10.1182/blood-2011-01-328567. Epub 2011 Jun 7.

30.

Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells.

Mullally A, Lane SW, Ball B, Megerdichian C, Okabe R, Al-Shahrour F, Paktinat M, Haydu JE, Housman E, Lord AM, Wernig G, Kharas MG, Mercher T, Kutok JL, Gilliland DG, Ebert BL.

Cancer Cell. 2010 Jun 15;17(6):584-96. doi: 10.1016/j.ccr.2010.05.015.

31.

Cdx4 is dispensable for murine adult hematopoietic stem cells but promotes MLL-AF9-mediated leukemogenesis.

Koo S, Huntly BJ, Wang Y, Chen J, Brumme K, Ball B, McKinney-Freeman SL, Yabuuchi A, Scholl C, Bansal D, Zon LI, Fröhling S, Daley GQ, Gilliland DG, Mercher T.

Haematologica. 2010 Oct;95(10):1642-50. doi: 10.3324/haematol.2010.023168. Epub 2010 May 21.

32.

Activating mutation in the TSLPR gene in B-cell precursor lymphoblastic leukemia.

Chapiro E, Russell L, Lainey E, Kaltenbach S, Ragu C, Della-Valle V, Hanssens K, Macintyre EA, Radford-Weiss I, Delabesse E, Cavé H, Mercher T, Harrison CJ, Nguyen-Khac F, Dubreuil P, Bernard OA.

Leukemia. 2010 Mar;24(3):642-5. doi: 10.1038/leu.2009.231. Epub 2009 Nov 12. No abstract available.

PMID:
19907440
33.

[The OTT-MAL fusion oncogene: another Notch in megakaryoblastic leukemia].

Bernard OA, Gilliland DG, Mercher T.

Med Sci (Paris). 2009 Aug-Sep;25(8-9):676-8. doi: 10.1051/medsci/2009258-9676. French. No abstract available.

34.

JAK3: a two-faced player in hematological disorders.

Cornejo MG, Boggon TJ, Mercher T.

Int J Biochem Cell Biol. 2009 Dec;41(12):2376-9. doi: 10.1016/j.biocel.2009.09.004. Epub 2009 Sep 9. Review.

35.

The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model.

Mercher T, Raffel GD, Moore SA, Cornejo MG, Baudry-Bluteau D, Cagnard N, Jesneck JL, Pikman Y, Cullen D, Williams IR, Akashi K, Shigematsu H, Bourquin JP, Giovannini M, Vainchenker W, Levine RL, Lee BH, Bernard OA, Gilliland DG.

J Clin Invest. 2009 Apr;119(4):852-64. doi: 10.1172/JCI35901. Epub 2009 Mar 16.

36.

Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models.

Cornejo MG, Kharas MG, Werneck MB, Le Bras S, Moore SA, Ball B, Beylot-Barry M, Rodig SJ, Aster JC, Lee BH, Cantor H, Merlio JP, Gilliland DG, Mercher T.

Blood. 2009 Mar 19;113(12):2746-54. doi: 10.1182/blood-2008-06-164368. Epub 2009 Jan 12.

37.

Notch signaling specifies megakaryocyte development from hematopoietic stem cells.

Mercher T, Cornejo MG, Sears C, Kindler T, Moore SA, Maillard I, Pear WS, Aster JC, Gilliland DG.

Cell Stem Cell. 2008 Sep 11;3(3):314-26. doi: 10.1016/j.stem.2008.07.010.

38.

OTT-MAL is a deregulated activator of serum response factor-dependent gene expression.

Descot A, Rex-Haffner M, Courtois G, Bluteau D, Menssen A, Mercher T, Bernard OA, Treisman R, Posern G.

Mol Cell Biol. 2008 Oct;28(20):6171-81. doi: 10.1128/MCB.00303-08. Epub 2008 Aug 18.

39.

[FoxO: stress or eternal life].

Tothova Z, Mercher T.

Med Sci (Paris). 2007 May;23(5):466-7. French. No abstract available.

40.

Ott1(Rbm15) has pleiotropic roles in hematopoietic development.

Raffel GD, Mercher T, Shigematsu H, Williams IR, Cullen DE, Akashi K, Bernard OA, Gilliland DG.

Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):6001-6. Epub 2007 Mar 21.

41.

A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia.

Gu TL, Mercher T, Tyner JW, Goss VL, Walters DK, Cornejo MG, Reeves C, Popova L, Lee K, Heinrich MC, Rush J, Daibata M, Miyoshi I, Gilliland DG, Druker BJ, Polakiewicz RD.

Blood. 2007 Jul 1;110(1):323-33. Epub 2007 Mar 14.

42.

Activating alleles of JAK3 in acute megakaryoblastic leukemia.

Walters DK, Mercher T, Gu TL, O'Hare T, Tyner JW, Loriaux M, Goss VL, Lee KA, Eide CA, Wong MJ, Stoffregen EP, McGreevey L, Nardone J, Moore SA, Crispino J, Boggon TJ, Heinrich MC, Deininger MW, Polakiewicz RD, Gilliland DG, Druker BJ.

Cancer Cell. 2006 Jul;10(1):65-75.

43.

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.

Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I, DeAngelo DJ, Clark JJ, Lee SJ, Golub TR, Wadleigh M, Gilliland DG, Levine RL.

PLoS Med. 2006 Jul;3(7):e270.

44.

JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model.

Mercher T, Wernig G, Moore SA, Levine RL, Gu TL, Fröhling S, Cullen D, Polakiewicz RD, Bernard OA, Boggon TJ, Lee BH, Gilliland DG.

Blood. 2006 Oct 15;108(8):2770-9. Epub 2006 Jun 27.

45.

Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.

Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG.

Blood. 2006 Jun 1;107(11):4274-81. Epub 2006 Feb 14.

46.

Interaction of the Epstein-Barr virus mRNA export factor EB2 with human Spen proteins SHARP, OTT1, and a novel member of the family, OTT3, links Spen proteins with splicing regulation and mRNA export.

Hiriart E, Gruffat H, Buisson M, Mikaelian I, Keppler S, Meresse P, Mercher T, Bernard OA, Sergeant A, Manet E.

J Biol Chem. 2005 Nov 4;280(44):36935-45. Epub 2005 Aug 29.

47.

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Fröhling S, Döhner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG.

Cancer Cell. 2005 Apr;7(4):387-97.

48.

A novel real-time RT-PCR assay for quantification of OTT-MAL fusion transcript reliable for diagnosis of t(1;22) and minimal residual disease (MRD) detection.

Ballerini P, Blaise A, Mercher T, Pellegrino B, Perot C, van den Akker J, Gatbois E, Adam M, Douay L, Berger R, Bernard O, Landman-Parker J.

Leukemia. 2003 Jun;17(6):1193-6. No abstract available.

PMID:
12764392
49.

[Molecular basis of the t(1;22)(p13;q13) specific for human acute megakaryoblastic leukemia].

Mercher T, Courtois G, Berger R, Bernard OA.

Pathol Biol (Paris). 2003 Feb;51(1):27-32. Review. French.

PMID:
12628289
50.

Recurrence of OTT-MAL fusion in t(1;22) of infant AML-M7.

Mercher T, Busson-Le Coniat M, Nguyen Khac F, Ballerini P, Mauchauffé M, Bui H, Pellegrino B, Radford I, Valensi F, Mugneret F, Dastugue N, Bernard OA, Berger R.

Genes Chromosomes Cancer. 2002 Jan;33(1):22-8.

PMID:
11746984

Supplemental Content

Loading ...
Support Center